VERA (Vera Therapeutics, Inc. Class A Common Stock) Stock Analysis - News
Vera Therapeutics, Inc. Class A Common Stock (VERA) is a publicly traded Healthcare sector company. As of May 21, 2026, VERA trades at $34.67 with a market cap of $2.47B and a P/E ratio of -7.31. VERA moved +4.15% today. Year to date, VERA is -26.45%; over the trailing twelve months it is +62.99%. Its 52-week range spans $18.53 to $56.05. Analyst consensus is strong buy with an average price target of $77.67. Rallies surfaces VERA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in VERA news today?
Vera Therapeutics Grants 40,250 Options and 20,125 RSUs at $35.51 Exercise Price: On May 4, Vera’s compensation committee granted non-qualified stock options to purchase 40,250 shares and RSUs underlying 20,125 shares to ten new employees under its 2024 Inducement Plan. Options carry a $35.51 exercise price and vest over four years, with 25% at first anniversary and monthly thereafter.
Vera Therapeutics Grants 40,250 Options and 20,125 RSUs at $35.51 Exercise Price: On May 4, Vera’s compensation committee granted non-qualified stock options to purchase 40,250 shares and RSUs underlying 20,125 shares to ten new employees under its 2024 Inducement Plan. Options carry a $35.51 exercise price and vest over four years, with 25% at first anniversary and monthly thereafter.
Does Rallies summarize VERA news?
Yes. Rallies summarizes VERA news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is VERA research on Rallies investment advice?
No. Rallies provides research, data, and educational context for VERA. It does not provide personalized investment advice.
